TILT-123 not checked
TILT Biotherapeutics Ltd. · Ad5/3-E2F-d24-hTNFa-IRES-hIL2
FollowEvery change as it happens, and a Monday email
Trials
4 active
6 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123”In the company’s words, NCT05271318 on ClinicalTrials.gov
- Tested for
- Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin and 5 more
- Main trialPhase 1/2
- “This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.”In the company’s words, NCT05271318 on ClinicalTrials.gov
- Other names
- Ad5/3-E2F-d24-hTNFa-IRES-hIL2
Other drugs for Platinum-refractory Ovarian Carcinoma
- PembrolizumabMerck & Co. · Phase 3
- EIK1001Eikon Therapeutics · Phase 2/3
- QL2107Qilu Pharmaceutical · Phase 3
- IFx-Hu2.0TuHURA Biosciences, Inc. · Phase 2/3
- FutibatinibTaiho · Phase 2/3
- MB11mAbxience Research S.L. · Phase 3
Coming up3
- NovPhase 1 trial completes · ClinicalTrials.gov
- DecPhase 1 trial completes · ClinicalTrials.gov
- Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Mar 2027 | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. | |
| Phase 1Active, not recruiting | 30 Jan 2026 | Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer | |
| Phase 1Active, not recruiting | Nov 2026 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma | |
| Phase 1Active, not recruiting | Dec 2026 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 | |
| Phase 1Completed | 12 Dec 2023 | TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma | |
| Phase 1Completed | 3 Sep 2025 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026